Top 5 Clinical Pearls in RA Management

Save

RheumNow Live 2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in Rheumatoid Arthritis."

APIPPRA Trial: Abatacept in at-risk rheumatoid arthritis patients

Save

Abatacept has been studied in seropositive clinically suspect arthralgia patients (at risk for rheumatoid arthritis) and shows the potential to delay or prevent the disease. 

Could Weight-Loss Drug Improve Hip Replacement Outcomes?

Save

The antidiabetic and weight-loss drug semaglutide (Ozempic, Wegovy, Rybelsus) either does or does not help patients undergoing total hip arthroplasty (THA) avoid complications and other poor outcomes, according to two retrospective studies presented here.

What are the Early Stages of Lupus?

Save

Incomplete lupus? Undifferentiated connective tissue disease? Pre-clinical autoimmune disease? During the lupus pod at RheumNow Live 2024, Dr. David Karp discussed the spectrum of autoimmune disease and the confusing terminology that is used with the complex world of early autoimmune disease. He cautioned against the traditional use of phrases such as incomplete lupus or undifferentiated connective tissue disease, which are heterogeneous and poorly defined.

Sex Disparities in PsA/SpA

Save

Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.

Co-management of Psoriatic Disease

Save

It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning session on choosing systemic therapies in psoriatic disease at RheumNow Live 2024 from dermatologist extraordinaire Dr. April Armstrong was therefore hugely insightful.

Oral IL-23 Inhibitor Effective in Psoriasis

Save

The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). 

VITAL Info on Autoimmune Disease (2.9.2024)

Save

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".

Poly-Refractory Rheumatoid Arthritis

Save

Refractory of difficult to treat (D2T-RA) rheumatoid arthritis (RA) comprises a minority of patients that can be categorized by clinical and imaging parameters to formulate a better therapeutic approach. 

Inflammatory Arthritis in Systemic Sclerosis is Problematic

Save

Inflammatory arthritis (IA) is a common manifestation in systemic sclerosis (SSc), affecting nearly one-third of patients.

VITAL Study - Autoimmune Prevention Requires Continued Supplements

Save

In the 2 years that followed the termination of the VITAL study, the preventative effect of vitamin D on incident autoimmune disease disappeared with supplement discontinuation; but n-3 fatty acid treated individuals had a sustained benefit in reducing the risk of autoimmune disease.

Determinants of Gout Flares

Save

Approximately 12 million US adults in the US have gout. Two recent literature reports highlight contributors to gout flares.